Diagnostic reagent for hepatitis C

Abstract: A diagnostic reagent for hepatitis C, which detects an antibody induced by infection of hepatitis C virus, characterized in that said diagnostic reagent comprises the second envelope protein or the first non-structural protein which is encoded by the gene of hepatitis C virus and has a suger chain. This invention also provide a method for detecting an anti-hepatitis C virus antibody. The use of the diagnostic reagent for hepatitis C according to the present invention makes highly sensitive diagnosis of hepatitis C possible.

Description: BACKGROUND OF THE INVENTION This invention relates to a diagnostic reagent for hepatitis C comprising an antigen protein translated from a genome of hepatitis C virus. More specifically, this invention relates to a diagnostic reagent for detecting an antibody against hepatitis C virus (hereinafter referred to as "HCV"), which comprises a protein encoded by a gene of HCV, wherein said protein is identified as a glycoprotein called the second envelope protein or the first non-structural protein (hereinafter referred to as "E2/NS1"). The first successful cloning of human hepatitis virus which had been called non-A, non-B hepatitis virus was accomplished in 1988 by Chiron Co., Ltd. U.S.A and the hepatitis virus was designated HCV. Further, Chiron Co., Ltd. succeeded in expressing in a yeast a fused protein which comprises at the C-terminal the polypeptide corresponding to the region having 363 amino acid residues from the third nonstructural protein (NS3) to the fourth non-structural protein (NS4) both of which are portions of nonstructural proteins of HCV and at the N-terminal human superoxide dismutase(European unexamined patent publication No. 318216) and, using this recombinant antigen, developed a diagnostic reagent for hepatitis C (Science, 244, 359-362, 362-364, (1989)). In Japan, the Japanese Red Cross Society has been using the diagnostic reagent in the screening of blood provided by donors, which is known as "C100-3 antibody test", in order to avoid post-transfusion hepatitis since the end of 1989. However, since not all samples are effectively screened only by C100-3 antibody test, post-transfusion hepatitis is not completely avoided. Subsequently, further investigation of HCV genomes derived from the serum of a Japanese patient by the cloning technique revealed that HCV prevailed in Japan is similar to HCV obtained by Chiron Co., Ltd. but a different strain (Protein, Nucleic acid and Enzyme, 36 , 1679-1691, (1991)). In addition, the use of the core protein (C) region of the structural protein, the third non-structural protein (NS3) region, the fifth non-structural protein region and the like have been proposed as more effective diagnostic reagents than C100-3 (Lancet, 337, 317-319, 1991 and Japanese unexamined patent publication (hereinafter referred to as "J. P. KOKAI") No. Hei 3-103180). In the June 1991 issue of "Viral Hepatitis and Liver Disease", an article was published "Serodiagnosis of Hepatitis C Viral Infection Using Recombinant-based Assays for Circulating Antibodies to Different Viral Proteins", Kuo et al, pages 347 - 349 which describes a diagnostic reagent comprising a fusion protein (expressed internally in recombinant yeast) corresponding to the E2-NS1 region. Table 1 of this article clearly shows that the reactivity of the fusion protein is extremely low (7.5%). EP-A-0472207 (Art. 54(3)/(4) disclosure) relates to an immunoassay for detecting the presence of an antibody to HCV utilizing recombinant antigenes representing distinct antigenic regions of the HCV genome. The NS1 region expressed in E.coli as a free fusion protein of an E.coli enzyme, CKS, is described therein. It does not describe the ES-NS1 region expressed in animal cells reacting with the serum of the patient of hepatitis C in a significantly high rate. EP-A-518313 (Art. 54(3)/(4) disclosure) discloses a novel gene encoding HCV polypeptide and a polypeptide encoded by the same. The C100-3 antibody test system has a disadvantage that the detection rate and the sensitivity are low as mentioned above. Although proteins derived from C, NS3 and NS5 regions have been proposed as more effective antigens for detection than C100-3, any satisfactory results have not yet been reported. Therefore, there is a need for a diagnostic reagent and a diagnostic method for hepatitis C, having a higher detection rate and sensitivity. SUMMARY OF THE INVENTION The inventors have conducted various investigations to obtain a diagnostic reagent for hepatitis C, having a higher detection rate and sensitivity. As a result, they have found that E2/NS1 protein having a sugar chain, which is obtained by expressing cDNA of E2/NS1 region in animal cells reacts with the serum of the patient of hepatitis C with a high rate in a fluorescent antibody test and accomplished the goals of the present invention. The high reaction rate of E2/NS1 region with the serum of the patient of hepatitis C was unexpected because the protein derived from E2/NS1 region is susceptible to the mutation of an amino acid sequence and, therefore, the protein expressed in E.coli has been considered to react with the serum of the patient of hepatitis C with a lower rate comparing with the proteins derived from the other regions of HCV and it has not been expected to use the protein for a diagnostic reagent. The present invention provides a diagnostic reagent for hepatitis C, which detects an antibody induced by infection of hepatitis C virus, characterised in that said diagnostic reagent comprises the second envelope protein or the first non-structural protein which is encoded by the genome of hepatitis C virus and has a sugar chain, wherein the second envelope protein or the first non-structural protein is produced by a CHO cell, a COS cell, a mouse L cell, a mouse C127 cell or a mouse FM3a cell. Methods for detecting according to claims 5 and 9 are also provided. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows the steps of constructing DNA fragment 1325SK containing the base sequence of clone J1-1325. Fig. 2 shows the steps of constructing plasmid pSR316EP. Fig. 3 shows the steps of constructing plasmid pSRNot. Fig. 4 shows the steps of constructing expression vector paSR1325X-3 having a DNA fragment coding for E2/NS1 protein. Fig. 5 shows the steps of constructing plasmid pHLp1. Fig. 6 shows the steps of constructing expression vector mulcos pHL16SR1325 having 16 DNA fragments coding for E2/NS1 protein. DETAILED EXPLANATION OF THE INVENTION E2/NS1 protein of the present invention is a protein derived from the region called the second envelope protein or the first nonstructural protein, which is encoded by the genome of HCV. Examples of the proteins are illustrated in SEQUENCE ID Nos.1-12 in SUQUENCE LISTING. Proteins obtained from such proteins by deleting, inserting, modifying or adding a part of amino acids are encompassed in the scope of the present invention provided that they maintain the reactivity with the serum of the patient of hepatitis C. (1) Method of preparing clones of cDNA derived from the serum of the patient of hepatitis C, which are shown in SEQUENCE ID Nos. 1-3 of SEQUENCE LISTING and determining the base sequence thereof Genes or DNA fragments coding for novel polypeptides, which are shown in SEQUENCE ID Nos. 1-3 of SEQUENCE LISTING can be prepared, for example, by a method described below. Since there exists a trace of HCV in the serum and the genome of HCV is expected to be RNA, it was expected that cloning by Okayama-Berg method or Gubler-Hoffman method of the prior art would be attended by difficulties and, therefore, the following method was conducted to ensure the cloning of the gene susceptible to mutation from a trace of the serum. The nucleic acid is extracted from the serum of the patient of hepatitis C as described in Example 1 later. Generally, it is preferred to use the serum having an OD value of 3.5 or more measured by a test kit of Ortho Inc. However, the present invention is not limited to the use of the serum having such an OD value. The serum is preferably mixed with transfer RNA (tRNA) as a carrier of virus RNA. The carrier is not limited to tRNA. Any polyribonucleoside can be used as carriers. If tRNA is used, there is an advantage that it can be rapidly confirmed by electrophoresis whether there is a required amount of tRNA having an intact length. By this confimation, it can also be confirmed whether virus RNA degradates after being mixed with tRNA as a carrier of virus RNA. As a technique of cloning cDNA from the nucleic acid, it is preferred to use polymerase chain reaction method developed by Saiki et al. (PCR method, Nature, 324, 126, (1986)). First of all, a reverse transcriptase is reacted using virus RNA as a template. In the reaction, any commercially available random primers or synthesized DNA having a base sequence similar to that of primer AS1 which is shown below may be used as a primer. A few bases at the 5' end of these sequences may be changed to other bases. Preferably, a few bases within 10 bases from the 5' end and more preferably, a few bases within 5 bases from the 5' end may be changed to other bases. In addition, 4-5 bases, preferably a few bases may be deleted from the sequences at the 5' end of these sequences. Furthermore, any 8-12 bases, preferably 5-6 bases, more preferably a few bases, may be added to the sequences at the 5' end of these sequences. PCR method is specifically carried out under the conditions described in Example 1. PCR method is carried out as described in Example 1 using the first complementary DNA (1st cDNA) thus obtained as a template to prepare a desired DNA fragment. The conditions of PCR method are suitably selected depending on the cicumstances. Representative examples of sense primers include the following one: "I" appearing in the sequence means inosine. A few bases at the 5' end of these sequences may be changed to other bases. Preferably, a few bases within 10 bases, more preferably, within 5 bases from the 5' end may be changed to other bases. In addition, 4-5 bases, preferably a few bases may be deleted from the sequences at the 5' end of these sequences. Furthermore, any 8-12 bases, preferably 5-6 bases, more preferably a few bases may be added to the sequences at the 5' end of these sequences. The DNA fragment thus obtained is inserted at one of cloning sites such as Sma I site of a cloning vector such as pUC19 according to conventional technique. Using a plasmid having this DNA fragment, the base sequences of at least 3 clones are determined independently regarding the both strands. The determination of the base sequences can be easily carried out by a dideoxy method using, for example, 7-deaza sequence kit availble from Takara Shuzo Co.,Ltd. or fluorescence sequencer GENESIS 2000 system available from Du Pont according to the protocol thereof. When the DNA fragment has a site which is considered difficult to determine the base sequence or has more than about 180 base pairs, a subcloning may be carried out according to conventional technique. SEQUENCE ID Nos.1-3 of SEQUENCE LISTING show the amino acid sequences of the proteins assumed from the base sequences of the DNA fragments thus determined. Clone J1-1325 (SEQUENCE ID No.1), clone N27, clone N19, H19 and Y19 (SEQUENCE ID No. 3) were prepared with the serums of different patients. Clone MX24 (SEQUENCE ID No.3) was prepared with a pool of the serums of the patients of hepatitis C. The clones shown in SEQUENCE ID Nos.1-3, which were prepared using a combination of primer S1 with primer AS1 correspond to the same region in the gene of HCV. Antigen proteins derived from E2/NS1 protein regions shown in SEQUENCE ID Nos.4-12 of SEQUENCE LISTING can also be used in the present invention. The antigen protein of SEQUENCE ID No.4 can be obtained by expressing cDNA described in Journal of Virology, 65 , 1105-1113, (1991). The antigen protein of SEQUENCE ID No.5 can be obtained by expressing cDNA described in Proceedings of the National Academy of Sciences of the USA, 87, 9524-9528, (1990). The antigen protein of SEQUENCE ID No.6 can be obtained by expressing cDNA described in The fiftieth general meeting of Japanese Cancer Society, 379, (1991). The antigen protein of SEQUENCE ID No.7 can be obtained by expressing cDNA described in European Patent No.0,388,232 (1990). The antigen proteins of SEQUENCE ID Nos.8 and 9 can be obtained by expressing cDNAs described in Proceedings of the National Academy of Sciences of the USA, 88, 3392-3396, (1991). The antigen proteins of SEQUENCE ID Nos.10 and 11 can be obtained by expressing cDNAs described in Japanese Journal of Experimental Medicine, 60 , 167-177, (1990). The antigen protein of SEQUENCE ID No.12 can be obtained by expressing cDNA described in Biochemical and Biophysical Research Communications, 175 , 220-228, (1991). The sequences shown in SEQUENCE ID Nos.4-12 correspond to the same region as that of the sequences shown in SEQUENCE ID Nos.1-3. (2) Expression of polypeptides encoded by the clones prepared in step (1) In order to produce E2/NS1 protein, it is necessary to select an appropriate host-vector system which is able to stably express the protein. Further, it is required that the expressed E2/NS1 protein has the same level of biological activity, that is, antigenicity as that of HCV. Considering that natural E2/NS1 protein is expected to be a glycoprotein and that E2/NS1 protein contains many cysteine residues and the positions of the thiol bonds between the cysteine residues and the higher-order structure of the protein are important to maintain the activity, it is essential to express the protein in such an animal cell host as CHO cell, COS cell, mouse L cell, mouse C127 cell and mouse FM3A cell, preferably CHO cell. When these cells are used as hosts, it is expected that processed E2/NS1 protein is produced by introducing E2/NS1 gene having a signal-like sequence of from the 32 position to the 44 position of the amino acid sequences shown in SEQUENCE ID Nos.1-12 into the cell. Expression plasmids for these animal host cells can be constructed as follows: As promoters in the animal cells, one can use the active-type promoter of adenovirus EIA gene (Biochemical Experiment Lecture, second series, Vol. 1, Techniques for gene investigations II, 189-190 (1986)), the early promoter of SV40, the late promoter of SV40, the promoter of apolipoprotein E gene and SR α promoter (Molecular and Celluar Biology, 8 , 466-472, (1988)), preferably the promoter of SV40 and SR α promoter. A DNA fragment of a gene coding for E2/NS1 protein containing the signal-like sequence is inserted downstream of the promoter in a direction of the transcription. When the expression vector of E2/NS1 protein is constructed, a ligated gene fragment of at least two gene fragments coding for E2/NS1 protein may be inserted downstream of the promoter. At least two units of DNA fragments ligated upstream of the 5' end of the D NA fragment of the gene coding for E2/NS1 protein with such a promoter as that of SV40 may be ligated together in the same direction of the transcription and then inserted in the vector. Polyadenylation sequence is required to be present downstream of the gene coding for E2/NS1 protein. For example, at least one of polyadenylation sequences derived from SV40 gene, β-globin gene or metallothionein gene is required to be present downstream of the gene coding for E2/NS1 protein. When at least two of the DNA fragments containing the gene coding for E2/NS1 protein ligated to the promoter are ligated, the polyadenylation sequence may be present at each 3' end of the gene coding for E2/NS1 protein. In transforming an animal cell such as CHO cell with this expression vector, the use of a selective marker is desired. Examples of the selective markers include DHFR gene expressing methotrexate resistance (Journal of Molecular Biology, 159, 601, (1982)), Neo gene expressing antibiotic G-418 resistance (Journal of Molecular Applied Genetics, 1, 327, (1982)), Ecogpt gene derived from E. coli, expressing mycophenol acid resistance (Proceedings of the National Academy of Sciences of the USA, 78 , 2072, (1981)), hph gene expressing antibiotic hygromycin resistance (Molecular and Celluar Biology, 5 , 410, (1985)) and the like. A promoter such as the aforementioned promoter derived from SV40 and the promoter of TK gene of Herpes virus is inserted upstream of the 5' end of each drug resistance gene. The aforementioned polyadenylation sequence are contained downstream of the 3' end of each drug resistance gene. When such a drug resistance gene is inserted in the expression vector of E2/NS1 protein, it may be inserted downstream of the polyadenylated site in the gene coding for E2/NS1 protein in a right direction or a reverse direction. These expression vectors do not require any co-transfection with another plasmid containing a selective marker gene in preparing a transfect. In the case where such a selective marker gene is not inserted in the expression vector of E2/NS1 protein, a vector having a selective marker of the transfect, such as pSV2neo (Journal of Molecular Applied Genetics, 1, 327, (1982)), pMBG (Nature, 294, 228, (1981)), p2gpt (Proceedings of the National Academy of Sciences of the USA, 78, 2072, (1981)), pAd-D26-1 (Journal of Molecular Biology, 159, 601, (1982)) and the like may be used together with the expression vector of E2/NS1 protein to conduct co-transfection. The transfect can be easily selected by gene expression of the selective marker gene. Examples of methods of introducing the expression vector into the animal cell include calcium phosphate method (Virology, 52 , 456, (1973)) and electroporation method (Journal of Membrane Biology, 10, 279, (1972)). Calcium phosphate method is used in general. The transfected animal cell can be cultured by a float culture or an adherent culture in the conventional manner. The cultivation can be conducted in a medium such as MEM, Ham, F-12 and the like in the presence of 5-10 % of serum or a suitable amount of insulin, dexamethasone and transferrin or in the absence of serum. The animal cell expressing E2/NS1 protein can be detected by fluorescent antibody technique using the serum of the patient according to the conventional method. The cloning is carried out by limiting dilution according to the conventional method to establish a cell line stably producing E2/NS1 protein. E2/NS1 protein derived from HCV gene, thus obtained can be used as HCV antigen which reacts immunologically with the serum containing HCV antibody and therefore, is useful for the confirmation or the detection of the presence of Anti-HCV antibody in samples including blood or serum. Examples of the immunoassays include RIA (radioimmunoassay), ELISA (enzyme-linked immunoadosorbent assay), fluorescent antibody technique, agglutination reaction including latex fixation, immuno precipitation and the like. In the detection, a labelled antibody is usually used. A labelling substance such as a fluorescent substance, a chemoluminescent substance, a radioactive substance, a dyeing substance and the like can be used. Accordingly, using the above E2/NS1 protein derived from HCV gene as an antigen, the diagnostic reagent for hepatitis C according to the present invention can be prepared. The reagent containing the protein having a sugar chain, which is derived from E2/NS1 region according to the present invention makes the confirmation or the detection of the presence of anti-HCV antibody in samples including blood or serum possible. The use of the reagent according to the present invention makes highly sensitive diagnosis of hepatitis C possible. The present invention will be explained in more detail with reference to the following non-limiting examples. Example 1 (1) Extraction of the nucleic acid from the serum of the patient of hepatitis C Twenty-five milliliters of a Tris buffer (50 mM Tris-HCl (pH 8.0), 1 mM EDTA and 100 mM NaCl) were added to 10 ml of the serum of the patient of hepatitis C, which showed at least 3.5 of an OD value by a HCV EIA kit available from Ortho Inc. After being mixed, the mixture was centrifuged at 20,000 x g at 20 °C for 20 minutes. The obtained supernatant was centrifuged at 100,000 x g at 20 °C for additional 5 hours. One point five milliliters of a Protenase K solution (1% sodium dodecyl sulfate, 10 mM EDTA, 10mM Tris-HCl (pH 7.5), 2 mg/ml Protenase K (available from Pharmacia Co.) and 6.6 µg of a yeast tRNA mixture) were added to the precipitate. After the precipitate was dissolved in the Protenase K solution, the obtained solution was maintained at 45°C for 90 minutes. The mixture was subjected at least four times to a phenol/chloroform treatment which comprises the steps of adding an equivalent amount of phenol/chloroform, violently agitating and then centrifuging the mixture to collect an aqueous phase containing a nucleic acid. Then, a chloroform treatment was carried out at least 2 times. To the obtained aqueous phase, one-tenth amount of 3M sodium acetate or an equivalent amount of 4M ammonium acetate, and 2.5-fold volume of ethanol were added and the mixture was left to stand at -20 °C overnight or -80 °C for at least 15 minutes. The mixture was centrifuged at 35,000 rpm for 4 hours by a SW41Ti rotor (available from Beckmann Co.) to collect a nucleic acid as a precipitate. (2) Synthesis of cDNA (2-1) Synthesis of an RNA sample After the nucleic acid obtained in step (1) was dried, 30 µl of water and 10 µl of ribonuclease inhibitor (100 units/ µl, available from Takara Shuzo Co., Ltd.) were added thereto to dissolve the nucleic acid. The following synthesis of cDNA was carried out using the obtained nucleic acid solution. (2-2) Synthesis of cDNA using an anti-sense primer To 2 µl of the aqueous solution of the nucleic acid prepared in step (2-1), 1 µl of an anti-sense primer (synthesized DNA primer AS1 ; 15 pmoles/ µ1), 2 µ1 of 10xRT buffer (100mM Tris-HCl (pH 8.3) and 500 mM of KCl), 4 µl of 25 mM MgCl 2 , 8 µl of 2.5 mM 4dNTP and 1 µl of water were added and the mixture was maintained at 65°C for 5 minutes and at room temperature for 5 minutes. Subsequently, 1 µl of 25 units of a reverse transcriptase (available from Life Science Co.) and 1 µl of a ribonuclease inhibitor (100 units/ µl, available from Takara Shuzo Co., Ltd.) were added to the mixture and then the resulting mixture was maintained at 37 °C for 20 minutes, then at 42 °C for 30 minutes and finally at 95 °C for 2 minutes. Immediately thereafter, the mixture was cooled to 0°C (Synthesis of complementary DNA). The DNA having a specific sequence was amplified using 10 µl of the DNA sample according to Saiki's method (Nature, 324, 126, (1986)), so-called PCR method as follows: Water was added to a mixture of 10 µl of the above DNA sample, 10 µl of 10xPCR buffer (100 mM of Tris-HCl (pH 8.3), 500 mM of KCl, 15 mM of MgCl 2 , and 1 % of gelatin), 8 µl of 2.5 mM 4dNTP, 2 µl of the synthesized DNA primer used in the synthesis of the complementary DNA (150 pmoles/ µl), 3 µl of a synthesized DNA primer corresponding to the DNA primer (15 pmoles/ µl) (which is complementary to the synthesized DNA primer used in the synthesis of the complementary DNA, i.e., the aforementioned primer S1) to prepare 100 µl of an aqueous solution. After the solution was maintained at 95°C for 5 minutes, it was cooled rapidly to 0°C. One minute after the cooling, the solution was mixed with 0.5 µl of Taq DNA polymerase (7 units/ µl, Trade Name "AmpliTaqTM" available from Takara Shuzo Co., Ltd.) and then mineral oil was layered on the mixture. This sample was incubated on a DNA Thermal Cycler available from Parkin Elmer Cetus Co. at 95 °C for 1 minute, at 40-55 °C for 1 minute, and at 72°C for 1-5 minutes for 25 cycles. After the sample was incubated finally at 72 °C for 7 minutes, the reaction aqueous solution was subjected to a phenol/chloroform treatment and a precipitation treatment with ethanol to obtain amplified DNA fragments. The above precipitation treatment with ethanol was carried out by mixing the aqueous phase with a one-tenth amount of 3 M sodium acetate or an equivalent amount of 4 M ammonium acetate together with a 2.5-fold volume of ethanol, centrifuging the mixture at 15,000 rpm at 4°C for 15 minutes by a rotor having a radius of about 5 cm and drying the precipitate. (3) Cloning of the amplified DNA fragments and Determination of the base sequences thereof At least 1 pmole of the DNA fragments obtained by the method described in step (2-2) was treated with T4 DNA polymerase (available from TOYOBO CO.,LTD) to make blunt ends (Molecular Cloning, 1982, Cold Spring Harbor Laboratory Press). After a phosphoric acid group was introduced into the DNA fragment at the 5' end with polynucleotidekinase (available from TOYOBO CO.,LTD) (Molecular Cloning, 1982, Cold Spring Harbor Laboratory Press), the DNA fragment was inserted at Sma I site present in the multicloning sites of pUC19 cloning vector using a ligation kit (available from Takara Shuzo Co., Ltd.). The vector DNA prepared in the following procedure was used in the ligation in an amount of 5-10 ng. pUC18 cloning vector was cleaved with restriction enzyme Sma I (available from TOYOBO CO.,LTD) and then subjected to a phenol/chloroform treatment and a precipitaion treatment with ethanol. Subsequently, this was treated with alkaline phosphatase (available from Boehringer Mannheim) to conduct the dephosphorylation at the 5' end (Molecular Cloning, 1982, Cold Spring Harbor Laboratory Press), followed by a phenol/chloroform treatment and a precipitation with ethanol. The competent cell of E.coli JM109 or DH5 (available from TOYOBO CO.,LTD) was transformed with the DNA prepared in the above procedure. The procedure of the transformation was according to the protocol of COMPETENT HIGH prepared by TOYOBO CO.,LTD. At least 20 transformants transformed with the pUC18 cloning vector having the DNA fragment obtained by the method described in step (2-2) using the combination of the aforementioned primers were prepared. Plasmid DNA pUC1325 shown in Fig. 1 was prepared from the obtained transformant in the conventional method and the base sequence of the plasmid was determined by a 7-deaza sequence kit available from Takara Shuzo Co., Ltd. or a fluorescence sequencer GENESIS 2000 system available from Du Pont. Two kinds of synthesized primers, 5'd(GTAAAACGACGGCCAGT)3' (SEQUENCE ID No. 15) and 5'd(CAGGAAACAGCTATGAC) 3' (SEQUENCE ID No. 16) were used to determine a base sequence of the + strand and that of the - strand of the DNA fragment. The DNA fragment had the same base sequence as that shown in SEQUENCE ID No. 1 of SEQUENCE LISTING. The amino acid sequence shown in SEQUENCE ID No. 1 of SEQUENCE LISTING is encoded by the + strand of the gene derived from HCV and inserted in the plasmid of the transformant. The amino acid sequence encoded by the DNA fragment obtained was compared with the reported sequences of hepatitis C viruses. In step (2-2) of Example 1, three clones were obtained from the serum of one patient. The determination of the base sequence of the clones reveals that the patient carries several kinds of viruses. (4) Preparation of a plasmid expressing E2/NS1 protein Figs. 1-6 show a procedure of preparing a plasmid expressing E2/NS1 protein. (4-1) Preparation of DNA fragment 1325SK The DNA fragment of clone 1325 contained in plasmid pUC1325 obtained in step (3) was inserted at Sma I site of pUC18 so that the fragment had KpnI site of pUC18 at the 5' end of the + strand of clone 1325 coding for E2/NS1 protein and Bam HI site of pUC18 at the 3' end. After complete digestion with restriction enzyme Hin dIII, the fragment was partially digested with restriction enzyme Bam HI to obtain a DNA fragment which was cleaved not at Bam HI site within the vector but only at another Bam HI site present in clone 1325. The DNA fragment contains from the Bam HI site present at the 5' end to the 3' end of clone 1325 which was the DNA fragment obtained in step (2-2), which was derived from the gene of HCV. Subsequently, as shown in Fig. 1, the DNA fragment was treated with T4 DNA polymerase to make blunt ends. After being ligated with Spe I linker consisting of the sequence of 5' pGGACTAGTCC 3' (SEQUENCE ID No. 17) (available from New England Biolab Co.), the fragment was cleaved with restriction enzyme Xba I (the Xba I site of the fragment was derived from plasmid pUC18). The following adaptor was ligated to Xba I site at the 3' end to obtain DNA fragment 1325SK. (4-2) Construction of plasmid pSRNot Expression vector pAC316 reported in Journal of Virology, 65 , 3015-3021, (1991) was cleaved with restriction enzyme Tth 111I at Tth 111I site present at the 3' end of 3' poly A region. T4 DNA polymerase was acted on the cleaved vector to make blunt ends. The fragment between Sal I site and Eco RI site of plasmid pmoRH (Fig. 2) reported by Ikeda et al (Gene, 71 , 19-27, (1988)) was cut out and T4 DNA polymerase was acted on the fragment to make blunt ends. As shown in Fig. 2, the DNA fragment derived from pAC316 and the DNA fragment derived from pmoRH were ligated together with Bgl II linker (available from Takara Shuzo Co., Ltd.) to obtain plasmid pSR316EP containing one Bgl II linker and one DNA fragment containing the early promoter of SV40 derived from pmoRH. As shown in Fig. 3, after plasmid pSR316EP was cleaved with restriction enzymes Hgi AI and Dra III, T4 DNA polymerase was acted on the plasmid to make blunt ends. Then, one Not I linker was introduced in the plasmid to obtain plasmid pSRNot (Fig. 3). Namely, Not I linker was prepared by synthesizing DNA having a sequence of 5' AGCGGCCGC 3' and phosphorylating the 5' end by kination (Molecular Cloning second eddition, 11.31-11.44, (1989), Cold Spring Harbor Labratory Press). Subsequently, dhfr gene was cut out from plasmid pCHD2L reported by Ikeda et al in Gene, 71, 19-27, (1988) using restriction enzymes Kpn I and Eco RV and Kpn I- Eco RV fragment of plasmid Charomid9-36 described in Proceedings of the National Academy of Sciences of the USA, 83 , 8664-8668, (1986) was inserted in the deleted dhfr gene region instead of the Kpn I- Eco RV fragment coding for dhfr gene as shown in Fig. 5 to obtain plasmid pChmBp1. The plasmid contains a polylinker derived from plasmid Charomid9-36. Then, plasmid pAG60 reported by Garapin et al. in Journal of Molecular Biology, 150 , 1-14, (1981) was cleaved with restriction enzyme Pvu II to obtain a Pvu II fragment coding for a neomycin gene. After plasmid pChmBp1 was cleaved with restriction enzyme Eco RV and then T4 DNA polymerase was acted to make blunt ends, the fragment obtained was ligated to the Pvu II fragment to obtain plasmid pHLp1 which contained the neomycin gene derived from plasmid pAG60 at the Eco RV site of plasmid pChmBp1 (Fig. 5). (4-3) Construction of expression vector paSR1325X-3 As shown in Fig. 4, after plasmid pSRNot obtained in step (4-2) was cleaved with restriction enzyme Not I and then with T4 DNA polymerase to make blunt ends, this was cleaved with restriction enzyme Kpn I. The obtained DNA fragment was ligated to DNA fragment 1325SK obtained in step (4-1) to obtain expression vector paSR1325X-3 having only one DNA fragment 1325SK (Fig. 4). (4-4) Construction of expression vector pHL16SR1325 As shown in Fig. 6, expression vector paSR1325X-3 obtained in step (4-3) was cleaved with restriction enzyme Sfi I to prepare two fragments one of which was an expression unit of clone 1325. The Sfi I sites were present in an initial promoter of SV40. Five µg of the Sfi I fragment having the expressin unit of clone 1325 was ligated to 50 ng of the fragment obtained by cleaving expression vector pHLp1 with restriction enzyme Sfi I in 10 µl of a reaction solution using a ligation kit available from Takara Shuzo Co., Ltd. according to a protocol for the ligation kit to obtain expression vector pHL16SR1325 (Fig. 6). The vector had successive sixteen DNA fragments 1325SK having at the Sfi I site of expression vector paSR1325X-3 the expression unit of clone 1325 which was a gene coding for E2/NS1 protein. In the vector, all of the DNA fragments 1325SK were inserted downstream of SV40 promoter of expression vector paSR1325X-3 in a direction of transcription. (5) Obtaining a cell line constantly expressing E2/NS1 protein Expression vector pHL16SR1325 prepared in step (4) was recovered from the recombinant E.coli DH1 strain, purified according to the conventional technique described in Molecular Cloning second edition, 1989, Cold Spring Harbor Laboratory Press to obtain a large amount of the expression plasmid DNA. CHO cells were transfected with the plasmid DNA according to the method described in Ausubel et al. (Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, Capter 9.1.1-9.1.4, (1987)) as follows: CHO cells were cultured in Ham F-12 medium containing 10 % of fetal calf serum (FCS) in a plate having a diamer of 6 cm until the cells were in semiconfluent condition. Then, the medium was removed from the plate and a DNA solution was dropwise added thereto. The DNA solution was previously prepared by the following procedure. Three hundreds µl of 2xHEBS solution (2xHEBS solution ; 1.6 % sodium chloride, 0.074 % potassium chloride, 0.05 % Na 2 HPO 4 · 12H 2 O, 0.2 % dextrose and 1 % HEPES (pH 7.05)) were mixed with 10 µg of the plasmid DNA in each plate and sterilized water was added to the mixture to prepare a solution of 570 µl. The solution was charged in an Eppendorf centrifuge tube. The DNA solution was violently agitated by a Vortex mixer for 1-2 seconds while adding 30 µl of 2.5 M calcium chloride solution thereto. The DNA solution was agitated by a Vortex mixer at about 10-minute intervals during being left to stand for 30 minutes. The obtained DNA solution was added to the aforementioned CHO cells and the CHO cells were left to stand at room temperature for 30 minutes. Then, 5 ml of Ham F-12 medium containing 10 % of FCS available from GIBCO Co. were added to the plate and the culture was incubated at 37 °C under air containing 5 % carbon dioxide for 4-5 hours. Subsequently, the medium was removed from the plate and the cells were washed with 5 ml of a 1xTBS ++ solution (1xTBS ++ solution ; 25 mM Tris-HCl (pH 7.5), 140 mM sodium chloride, 5mM potassium chloride, 0.6 mM disodium hydrogen phosphate, 0.08 mM calcium chloride and 0.08 mM magnesium chloride). After the 1xTBS ++ solution was removed, 5 ml of a 1xTBS ++ solution containing 20 % of glycerol was added to the cells and the culture was left to stand at room temperature for 1-2 minutes. After the supernatant was removed from the plate, the cells were washed again with 5 ml of a 1xTBS ++ solution and cultured in 5 ml of fresh Ham F-12 medium containing 10 % of FCS in the plate at 37 °C under air containing 5 % carbon dioxide for 48 hours. Then, the medium was removed and the cells were washed with 5 ml of a 1xTBS ++ solution. The cells were treated with a trypsin-EDTA solution (available from Sigma Co.) and left to stand at room temperature for 30 seconds. Five minutes after the trypsin-EDTA solution was removed, the cells attached to the wall of the plate were peeled adding 5 ml of Ham F-12 medium containing 10 % of FCS. The cells cultured in one plate having a diameter of 5 cm were divided in ten plates having a diameter of 9 cm and cultured in the plates containing drug G418 (G418 sulfate (GENETICIN) available from GIBCO Co.) in a concentration of 600 µg /ml. Ten days after the cultivation, grown cells having G418 resistance were isolated and cultured for about 7 days in 1 ml of Ham F-12 medium containing 10 % of FCS in a 24 well titer plate each well of which has an area of about 3.1 cm 2 . A part of the cells were clutured on slide glass (Lab-Tek Chamber Slides, Nunc4808 available from Japan Inter Med Co.) overnight. After being rinsed with phosphate buffered saline (PBS), the slide glass was immersed in cold actone-methanol (1:1) solution and maintained at -20 °C for 15 minutes to fix the cells. The cells fixed on the slide glass were reacted with the serum of the patient of hepatitis C 20-fold diluted with PBS at 37°C for 30 minutes. Then, the slide glass was washed three times with PBS for 5 minutes and reacted with FITC-labelled rabbit anti-human IgG (available from Daco Japan Co.) 50-fold diluted with PBS at 37 °C for 30 minutes. The slide glass was washed three times with PBS for 5 minutes and dried by putting the slide glass between two pieces of filter paper. After the slide glass was sealed with glycerin, the cells on the slide glass were observed under a fluorescence microscope. Screening positive cells as descrived above, successive three times of limiting dilution were carried out to establish cell line 13L20 constantly producing E2/NS1 protein. (6) Study of the reactivity of 13L20 cells with the serum of the patient of hepatitis C After 13L20 cells established in step (5) were cultured on Lab-Tek Chamber Slides (Lab-Tek Chamber Slides, Nunc4808 available from Japan Inter Med Co.) overnight and then fixed with a cold acetone-methanol solution, the fixed cells were reacted with 59 serum samples of the patients of hepatitis C. Then, the cells were washed as described above and reacted with the secondary antibody. The observation under a fluorescence microscope revealed that 53 samples were positive. Among the 59 serum samples, 6 samples were judged to be positive using CHO cells constantly producing the first envelope region of HCV. Example 2 Using as a template the DNA fragment described in Example 11 (3) of the specification of European Patent Application No. 92109812.5 (EP-A-518313) filed on June 11, 1992 (TITLE OF THE INVENTION "Gene or DNA fragments derived from hepatitis C virus, polypeptides encoded thereby, and method of producing thereof"), PCR reaction was carried out in the same manner as that of Example 1 using the same primer to obtain a DNA fragment corresponding the same region as that of clone J1-1325 shown in SEQUENCE ID No. 1 of SEQUENCE LISTING. The region was a DNA fragment encoding for E2/NS1 protein like clone J1-1325. For example, using as a template the DNA fragment clone N27MX24A-1 having a base sequence shown in SEQUENCE ID No. 31 of SEQUENCE LISTING described in the specification of the aforementioned European Patent Application filed on June 11, 1992, plasmid pUCN27MX24A-2 was obtained. The base sequence of the DNA fragment coding for E2/NS1 protein, which was cloned in the plasmid is shown in SEQUENCE ID No. 2 of SEQUENCE LISTING. In addition, MK2724A2 cell line constantly producing E2/NS1 protein was establised by the same procedure as that described in steps (4) and (5) of Example 1. The reactivity of the same samples as Example 1 with the cell line was estimated by the same method as that described in step (6) of Example 1. Results similar to those obtained in step (6) of Example 1 were obtained. SEQUENCE LISTING (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: J1-1325 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: N27MX24A-2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: protein (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: N27,N19,H19,Y19,MX24 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: BK164 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: HCV-J (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: HCV-RNA33 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: HCV1 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: H77 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: H90 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 523 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: J1(JM) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 523 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (iv) ANTI-SENSE: No (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (B) CLONE: J4 (JM) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino acids (B) TYPE: protein (vi) ORIGINAL SOURCE: (A) ORIGIN: Hepatitis C virus (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) ( ) SEQUENCE CHARACTERISTIC: N represents inosine. (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULAR TYPE: the other nucleic acid (synthesized DNA for PCR) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Claims: A diagnostic reagent for hepatitis C, which detects an antibody induced by infection of hepatitis C virus, characterized in that said diagnostic reagent comprises the second envelope protein or the first non-structural protein which is encoded by the gene of hepatitis C virus and has a sugar chain, wherein the secpnd envelope protein or the first non-structural protein is produced by a CHO cell, a COS cell, a mouse L cell, a mouse C127 cell or a mouse FM3A cell. The diagnostic reagent for hepatitis C according to Claim 1, wherein the second envelope protein or the first non-structural protein is represented by an amino acid sequence selected from SEQUENCE ID Nos.1-12 of SEQUENCE LISTING or an amino acid sequence having the same as a part thereof. The diagnostic reagent for hepatitis C according to Claim 1, wherein the second envelope protein or the first non-structural protein is encoded by a base sequence selected from SEQUENCE ID Nos.1-2, and 4-11 of SEQUENCE LISTING. The diagnostic reagent for hepatitis C according to Claim 1, wherein the cell is CHO cell. A method for detecting an anti-hepatitis C virus antibody, wherein the second envelope protein or the first non-structural protein which is encoded by the gene of hepatitis C virus and has a sugar chain is used as an antigen to detect the antibody specific to said antigen, wherein the second envelope protein or the first non-structural protein is produced by a CHO cell, a COS cell, a mouse L cell, a mouse C127 cell or a mouse FM3A cell. The method according to Claim 5, wherein the second envelope protein or the first non-structural protein is represented by an amino acid sequence selected from SEQUENCE ID Nos.1-12 of SEQUENCE LISTING or an amino acid sequence having the same as a part thereof. The method according to Claim 5, wherein the second envelop protein or the first non-structural protein is encoded by a base sequence selected from SEQUENCE ID Nos.1-2, and 4-11 of SEQUENCE LISTING. The method according to Claim 5, wherein the cell is CHO cell. A method for detecting an anti-hepatitis C virus antibody, which comprises the steps of contacting a sample with the second envelope protein or the first non-structural protein which is encoded by the gene of hepatitis C virus and has a sugar chain, wherein the second envelope protein or the first non-structural protein is produced a CHO cell, a COS cell, a mouse L cell, a mouse C127 cell or a mouse FM3A cell, under the conditions that the second envelope protein or the first non-structural protein is bound to the anti-hepatitis C virus antibody to form an immunological complex and measuring the formation of the immunological complex to confirm the presence of the anti-hepatitis C virus antibody in the sample. The method according to Claim 9, wherein the formation of the immunological complex is measured by RIA, ELISA, fluorescent antibody technique, agglutination reaction, or immune precipitation.

Inventors: HARADA SHIZUKO, HONDA YOSHIKAZU, MIYAMURA TATSUO, SAITO IZUMU, HARADA, SHIZUKO, HONDA, YOSHIKAZU, MIYAMURA, TATSUO, SAITO, IZUMU
Applicants: JP AGENCY OF NAT INST OF HEALT, JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY OF NATIONAL INSTITUTE OF HEALTH
Application year: 1992
Main classification: G01N33
IPC codes: C12N15, G01N33, C07K14